Cellectis 1 article

The biotechnology profile of Cellectis is built around TALEN genome editing and allogeneic CAR-T cell therapy, placing it in targeted genetic medicine rather than conventional gene addition. The platform further combines UCART gene-edited T cells with off-the-shelf engineered T cells, with T-cell receptor knockout engineering defining an important delivery, nuclease, cell-processing or disease-specific aspect of the editing strategy. CRISPR systems, editing chemistries and therapeutic products remain separate tags; the editing platform of Cellectis also includes hematologic malignancy immunotherapy.